Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment

Area of Science:

• Oncology
• Pharmacology
• Epigenetics

Background:

• Cancer cells rely on epigenetic pathways for survival.
• Epigenetic drugs offer targeted therapy distinct from DNA sequence targeting.
• Approved epigenetic drugs are mainly for hematological cancers, with limited efficacy in solid tumors as single agents.

Purpose of the Study:

• To review the anti-angiogenic activity of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors.
• To discuss the combination of these epigenetic inhibitors with other targeted anti-angiogenic therapeutics for solid tumors.
• To critically evaluate the role of these combinations in inhibiting tumor angiogenesis and their advantages over broad-acting anticancer agents.

Main Methods:

• Literature review focusing on epigenetic inhibitors (HDAC and DNMT inhibitors).
• Analysis of studies investigating combinations of epigenetic drugs with targeted anti-angiogenic agents.
• Evaluation of anti-angiogenic mechanisms and clinical potential in solid tumors.

Main Results:

• HDAC and DNMT inhibitors exhibit anti-angiogenic properties.
• Combinations of epigenetic drugs with targeted anti-angiogenic agents show promising activity in preclinical and clinical settings for solid tumors.
• These combined therapies demonstrate potential for more effective tumor angiogenesis inhibition.

Conclusions:

• Epigenetic drugs, particularly in combination with targeted anti-angiogenic therapies, represent a promising strategy for solid tumor treatment.
• Targeted inhibition of tumor angiogenesis by these combined agents offers advantages over traditional chemotherapy.
• Further research into HDAC and DNMT inhibitors in combination therapies is warranted for solid tumor management.